Elan Sells Back Frova Rights; Vernalis Plans Menstrual Migraine Filing In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Vernalis is seeking a new U.S. marketing partner for the triptan. Elan will use proceeds from the $55 mil. deal toward the Antegren launch.